Go Pro

Keen Vision Acquisition (KVAC) Competitors

Keen Vision Acquisition logo
$12.32 +0.14 (+1.15%)
Closing price 06/29/2026 03:55 PM Eastern
Extended Trading
$12.14 -0.18 (-1.42%)
As of 03:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

KVAC vs. ITHA, OACC, PLMK, DMAA, and GETY

Should you buy Keen Vision Acquisition stock or one of its competitors? MarketBeat compares Keen Vision Acquisition with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Keen Vision Acquisition include ITHAX Acquisition Corp III (ITHA), Oaktree Acquisition Corp. III Life Sciences (OACC), Plum Acquisition Corp. IV (PLMK), Drugs Made In America Acquisition (DMAA), and Getty Images (GETY). These companies are all part of the "trading" industry.

How does Keen Vision Acquisition compare to ITHAX Acquisition Corp III?

Keen Vision Acquisition (NASDAQ:KVAC) and ITHAX Acquisition Corp III (NASDAQ:ITHA) are both small-cap financial services companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Keen Vision AcquisitionN/AN/AN/AN/AN/A
ITHAX Acquisition Corp IIIN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Keen Vision AcquisitionN/A N/A N/A
ITHAX Acquisition Corp III N/A N/A N/A

51.7% of Keen Vision Acquisition shares are held by institutional investors. 47.8% of Keen Vision Acquisition shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Keen Vision Acquisition
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
ITHAX Acquisition Corp III
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Keen Vision Acquisition had 1 more articles in the media than ITHAX Acquisition Corp III. MarketBeat recorded 3 mentions for Keen Vision Acquisition and 2 mentions for ITHAX Acquisition Corp III. Keen Vision Acquisition's average media sentiment score of 1.48 beat ITHAX Acquisition Corp III's score of 0.94 indicating that Keen Vision Acquisition is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Keen Vision Acquisition
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ITHAX Acquisition Corp III
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Keen Vision Acquisition beats ITHAX Acquisition Corp III on 5 of the 5 factors compared between the two stocks.

How does Keen Vision Acquisition compare to Oaktree Acquisition Corp. III Life Sciences?

Keen Vision Acquisition (NASDAQ:KVAC) and Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) are both small-cap financial services companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

Company Net Margins Return on Equity Return on Assets
Keen Vision AcquisitionN/A N/A N/A
Oaktree Acquisition Corp. III Life Sciences N/A N/A N/A

Keen Vision Acquisition has a beta of -0.03, meaning that its share price is 103% less volatile than the broader market. Comparatively, Oaktree Acquisition Corp. III Life Sciences has a beta of -0.01, meaning that its share price is 101% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Keen Vision Acquisition
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Oaktree Acquisition Corp. III Life Sciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Keen Vision Acquisition had 2 more articles in the media than Oaktree Acquisition Corp. III Life Sciences. MarketBeat recorded 3 mentions for Keen Vision Acquisition and 1 mentions for Oaktree Acquisition Corp. III Life Sciences. Oaktree Acquisition Corp. III Life Sciences' average media sentiment score of 1.89 beat Keen Vision Acquisition's score of 1.48 indicating that Oaktree Acquisition Corp. III Life Sciences is being referred to more favorably in the news media.

Company Overall Sentiment
Keen Vision Acquisition Positive
Oaktree Acquisition Corp. III Life Sciences Very Positive

51.7% of Keen Vision Acquisition shares are owned by institutional investors. 47.8% of Keen Vision Acquisition shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Keen Vision AcquisitionN/AN/AN/AN/AN/A
Oaktree Acquisition Corp. III Life SciencesN/AN/AN/AN/AN/A

Summary

Keen Vision Acquisition beats Oaktree Acquisition Corp. III Life Sciences on 4 of the 6 factors compared between the two stocks.

How does Keen Vision Acquisition compare to Plum Acquisition Corp. IV?

Plum Acquisition Corp. IV (NASDAQ:PLMK) and Keen Vision Acquisition (NASDAQ:KVAC) are both small-cap financial services companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Plum Acquisition Corp. IV has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market. Comparatively, Keen Vision Acquisition has a beta of -0.03, suggesting that its stock price is 103% less volatile than the broader market.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Plum Acquisition Corp. IVN/AN/AN/AN/AN/A
Keen Vision AcquisitionN/AN/AN/AN/AN/A

In the previous week, Keen Vision Acquisition had 1 more articles in the media than Plum Acquisition Corp. IV. MarketBeat recorded 3 mentions for Keen Vision Acquisition and 2 mentions for Plum Acquisition Corp. IV. Keen Vision Acquisition's average media sentiment score of 1.48 beat Plum Acquisition Corp. IV's score of 1.44 indicating that Keen Vision Acquisition is being referred to more favorably in the news media.

Company Overall Sentiment
Plum Acquisition Corp. IV Positive
Keen Vision Acquisition Positive

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Plum Acquisition Corp. IV
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Keen Vision Acquisition
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

51.7% of Keen Vision Acquisition shares are owned by institutional investors. 27.9% of Plum Acquisition Corp. IV shares are owned by company insiders. Comparatively, 47.8% of Keen Vision Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
Plum Acquisition Corp. IVN/A N/A N/A
Keen Vision Acquisition N/A N/A N/A

Summary

Keen Vision Acquisition beats Plum Acquisition Corp. IV on 5 of the 6 factors compared between the two stocks.

How does Keen Vision Acquisition compare to Drugs Made In America Acquisition?

Keen Vision Acquisition (NASDAQ:KVAC) and Drugs Made In America Acquisition (NASDAQ:DMAA) are both small-cap financial services companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Keen Vision AcquisitionN/AN/AN/AN/AN/A
Drugs Made In America AcquisitionN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Keen Vision AcquisitionN/A N/A N/A
Drugs Made In America Acquisition N/A N/A N/A

51.7% of Keen Vision Acquisition shares are owned by institutional investors. 47.8% of Keen Vision Acquisition shares are owned by company insiders. Comparatively, 0.9% of Drugs Made In America Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Keen Vision Acquisition
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Drugs Made In America Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Keen Vision Acquisition had 2 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 3 mentions for Keen Vision Acquisition and 1 mentions for Drugs Made In America Acquisition. Drugs Made In America Acquisition's average media sentiment score of 1.87 beat Keen Vision Acquisition's score of 1.48 indicating that Drugs Made In America Acquisition is being referred to more favorably in the news media.

Company Overall Sentiment
Keen Vision Acquisition Positive
Drugs Made In America Acquisition Very Positive

Keen Vision Acquisition has a beta of -0.03, meaning that its share price is 103% less volatile than the broader market. Comparatively, Drugs Made In America Acquisition has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market.

Summary

Keen Vision Acquisition beats Drugs Made In America Acquisition on 4 of the 6 factors compared between the two stocks.

How does Keen Vision Acquisition compare to Getty Images?

Getty Images (NYSE:GETY) and Keen Vision Acquisition (NASDAQ:KVAC) are both small-cap trading companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

Getty Images currently has a consensus price target of $3.78, indicating a potential upside of 302.48%. Given Getty Images' higher probable upside, analysts clearly believe Getty Images is more favorable than Keen Vision Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Getty Images
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Keen Vision Acquisition
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

45.8% of Getty Images shares are owned by institutional investors. Comparatively, 51.7% of Keen Vision Acquisition shares are owned by institutional investors. 12.5% of Getty Images shares are owned by company insiders. Comparatively, 47.8% of Keen Vision Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Keen Vision Acquisition has lower revenue, but higher earnings than Getty Images.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Getty Images$983.79M0.40-$206.12M-$0.26N/A
Keen Vision AcquisitionN/AN/AN/AN/AN/A

Keen Vision Acquisition has a net margin of 0.00% compared to Getty Images' net margin of -10.94%. Keen Vision Acquisition's return on equity of 0.00% beat Getty Images' return on equity.

Company Net Margins Return on Equity Return on Assets
Getty Images-10.94% -17.01% -3.70%
Keen Vision Acquisition N/A N/A N/A

In the previous week, Getty Images had 9 more articles in the media than Keen Vision Acquisition. MarketBeat recorded 12 mentions for Getty Images and 3 mentions for Keen Vision Acquisition. Keen Vision Acquisition's average media sentiment score of 1.48 beat Getty Images' score of 0.02 indicating that Keen Vision Acquisition is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Getty Images
2 Very Positive mention(s)
0 Positive mention(s)
8 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Keen Vision Acquisition
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Getty Images has a beta of 2.03, meaning that its stock price is 103% more volatile than the broader market. Comparatively, Keen Vision Acquisition has a beta of -0.03, meaning that its stock price is 103% less volatile than the broader market.

Summary

Keen Vision Acquisition beats Getty Images on 6 of the 11 factors compared between the two stocks.

Get Keen Vision Acquisition News Delivered to You Automatically

Sign up to receive the latest news and ratings for KVAC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KVAC vs. The Competition

MetricKeen Vision AcquisitionUNCLASSIFIED IndustryFinancial SectorNASDAQ Exchange
Market Cap$67.07M$154.47M$6.09B$12.20B
Dividend YieldN/AN/A5.25%6.22%
P/E RatioN/A42.5829.3124.38
Price / SalesN/A190.351,468.97100.30
Price / CashN/A57.6248.6036.93
Price / BookN/A37.166.546.49
Net IncomeN/A-$20.48M$1.13B$336.61M
7 Day Performance0.61%-0.02%0.19%1.20%
1 Month Performance0.49%-4.47%0.08%0.20%
1 Year Performance8.36%-1.58%17.75%30.15%

Keen Vision Acquisition Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KVAC
Keen Vision Acquisition
2.3057 of 5 stars
$12.32
+1.1%
N/A+8.4%$67.07MN/AN/AN/A
ITHA
ITHAX Acquisition Corp III
N/A$9.97
-0.3%
N/AN/A$266.67MN/AN/A1
OACC
Oaktree Acquisition Corp. III Life Sciences
N/A$10.67
+0.2%
N/A+2.0%$261.81MN/AN/AN/A
PLMK
Plum Acquisition Corp. IV
1.6219 of 5 stars
$10.67
+0.1%
N/A+3.1%$258.43MN/AN/A2
DMAA
Drugs Made In America Acquisition
1.3541 of 5 stars
$10.63
+0.1%
N/AN/A$257.82MN/AN/A2

Related Companies and Tools


This page (NASDAQ:KVAC) was last updated on 6/30/2026 by MarketBeat.com Staff.
From Our Partners